These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 36876740)

  • 1. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
    Nissen SE; Lincoff AM; Brennan D; Ray KK; Mason D; Kastelein JJP; Thompson PD; Libby P; Cho L; Plutzky J; Bays HE; Moriarty PM; Menon V; Grobbee DE; Louie MJ; Chen CF; Li N; Bloedon L; Robinson P; Horner M; Sasiela WJ; McCluskey J; Davey D; Fajardo-Campos P; Petrovic P; Fedacko J; Zmuda W; Lukyanov Y; Nicholls SJ;
    N Engl J Med; 2023 Apr; 388(15):1353-1364. PubMed ID: 36876740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
    Nicholls SJ; Nelson AJ; Lincoff AM; Brennan D; Ray KK; Cho L; Menon V; Li N; Bloedon L; Nissen SE
    JAMA Cardiol; 2024 Mar; 9(3):245-253. PubMed ID: 38231501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients.
    Nissen SE; Menon V; Nicholls SJ; Brennan D; Laffin L; Ridker P; Ray KK; Mason D; Kastelein JJP; Cho L; Libby P; Li N; Foody J; Louie MJ; Lincoff AM
    JAMA; 2023 Jul; 330(2):131-140. PubMed ID: 37354546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial.
    Ray KK; Nicholls SJ; Li N; Louie MJ; Brennan D; Lincoff AM; Nissen SE;
    Lancet Diabetes Endocrinol; 2024 Jan; 12(1):19-28. PubMed ID: 38061370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs.
    Lincoff AM; Ray KK; Sasiela WJ; Haddad T; Nicholls SJ; Li N; Cho L; Mason D; Libby P; Goodman SG; Nissen SE
    J Am Coll Cardiol; 2024 Jul; 84(2):152-162. PubMed ID: 38960508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
    Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
    N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.
    Nicholls S; Lincoff AM; Bays HE; Cho L; Grobbee DE; Kastelein JJ; Libby P; Moriarty PM; Plutzky J; Ray KK; Thompson PD; Sasiela W; Mason D; McCluskey J; Davey D; Wolski K; Nissen SE
    Am Heart J; 2021 May; 235():104-112. PubMed ID: 33470195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
    Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
    J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
    Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
    JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.
    Ridker PM; Lei L; Louie MJ; Haddad T; Nicholls SJ; Lincoff AM; Libby P; Nissen SE;
    Circulation; 2024 Jan; 149(1):28-35. PubMed ID: 37929602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
    N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review.
    Duarte Lau F; Giugliano RP
    JAMA Cardiol; 2023 Sep; 8(9):879-887. PubMed ID: 37585218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
    N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance.
    Bays HE; Bloedon LT; Lin G; Powell HA; Louie MJ; Nicholls SJ; Lincoff AM; Nissen SE
    J Clin Lipidol; 2024; 18(1):e59-e69. PubMed ID: 37951797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.
    Gencer B; Mach F; Murphy SA; De Ferrari GM; Huber K; Lewis BS; Ferreira J; Kurtz CE; Wang H; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
    JAMA Cardiol; 2020 Aug; 5(8):952-957. PubMed ID: 32432684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of extended-release niacin with laropiprant in high-risk patients.
    ; Landray MJ; Haynes R; Hopewell JC; Parish S; Aung T; Tomson J; Wallendszus K; Craig M; Jiang L; Collins R; Armitage J
    N Engl J Med; 2014 Jul; 371(3):203-12. PubMed ID: 25014686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials.
    Cordero A; Fernandez Olmo R; Santos-Gallego CG; Fácila L; Bonanad C; Castellano JM; Rodriguez-Mañero M; Seijas-Amigo J; González-Juanatey JR; Badimon JJ
    Am J Cardiol; 2023 Oct; 205():321-324. PubMed ID: 37633067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.